An Open Label Study of the Safety During Treatment With Tocilizumab (TCZ), in Combination With Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Rheumatoid Arthritis.
Phase of Trial: Phase III
Latest Information Update: 03 Feb 2014
At a glance
- Drugs Tocilizumab (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Roche
- 15 Aug 2012 Actual patient number changed from 31 to 61 as reported by ClinicalTrials.gov.
- 18 Jul 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
- 18 Jul 2012 Actual initiation date changed from Sep 2010 to Oct 2010, as reported by ClinicalTrials.gov.